Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics is a clinical-stage biopharmaceutical company with positive outlook due to its use of precision medicine in developing anti-cancer therapeutics, specifically its lead program Stenoparib which has shown promising results in advanced ovarian cancer and is now being trialed for recurrent Small Cell Lung Cancer. The company's proprietary Drug Response Predictor (DRP) platform and Stenoparib DRP companion diagnostic give it a competitive advantage in identifying and selecting patients for enrollment, and the large market potential for PARP inhibitors in multiple oncology indications provides strong potential for growth. Additionally, the company has a solid balance sheet with enough cash to support its operations into late 2026.

Bears say

Allarity Therapeutics is a clinical stage, precision medicine pharmaceutical company that focuses on developing anti-cancer therapeutics, with a lead program in developing Stenoparib for ovarian cancer. The company has faced challenges in its development with recent negative adjustments to EPS estimates. Although the company's DRP platform has shown potential for personalized and precision medicine, the high risks and long development timeline for Stenoparib may outweigh potential rewards, especially considering the large market potential for PARP inhibitors in the treatment of multiple cancers. Additionally, the company's financials revealed minimal revenue and substantial loss, raising concerns about the sustainability of its operations.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.